Review summarizes therapeutic strategies targeting cGAS-STING-macrophage axis for renal fibrosis and chronic kidney disease.

This publication is a narrative review focusing on renal fibrosis and chronic kidney disease. The authors synthesize current knowledge regarding the cGAS-STING-macrophage axis as a therapeutic target. The scope encompasses small molecule inhibitors, nanocarrier-based delivery systems, and gene editing technologies. The review does not report specific study populations, sample sizes, or follow-up durations. No comparator groups were defined in the source material.

Key arguments highlight the potential of these modalities to modulate the cGAS-STING-macrophage axis. The authors discuss how these interventions might address underlying pathophysiology. However, the text notes significant complexity in molecular mechanisms. There are also differences in research results reported in the literature. These discrepancies complicate the interpretation of efficacy. Variability in outcomes suggests heterogeneity in study designs.

Limitations acknowledged by the authors include challenges in clinical translation. The review does not provide data on adverse events, serious adverse events, or discontinuations. Safety and tolerability profiles are not reported. The authors emphasize that precise therapeutic development requires further investigation. Uncertainty regarding long-term effects persists.

Practice relevance is described as providing a foundation for future development. Clinicians should recognize that these strategies are not yet established standard of care. The evidence base remains preliminary without randomized controlled trial data. Cautious interpretation is necessary given the observational nature of the underlying research. Further research is needed to validate efficacy.